Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:31 PM
Ignite Modification Date:
2025-12-24 @ 4:31 PM
NCT ID:
NCT05960266
Eligibility Criteria:
Inclusion Criteria:
* Patients who have seasonal grass-pollen-induced rhinoconjunctivitis as confirmed by patient history and type-1-sensitization to grass-pollen in skin and/or serum.
* Patients that undergo pre-seasonal short-term scheme with Polvac™ SCIT at the USZ Allergy Unit in autumn and winter 2023 for treatment of allergic rhinoconjunctivitis.
Informed Consent as documented by signature.
* Patients are between 18 and 55 years of age when they sign the informed consent.
Exclusion Criteria:
* Known or suspected allergy to additives to the study product
* Known intolerance or allergy to phenol
* Planned depot steroid injection for treatment of allergic rhinoconjunctivitis
* Uncontrolled asthma or severe asthma with post bronchodilator FEV1\<70%, decided by the investigator
* Pulmonary disease with post bronchodilator FEV1 \< 70 % of predicted
* Pulmonary disease, perennial or seasonal, with daily use of more than 800 microgram inhaled budesonide/day (or equivalent)
* Treatment with omalizumab or other biologics for allergy, AD, urticaria or asthma.
* Allergic reaction within the last 4 days or anaphylaxis within last month before planned ILIT or SCIT injection.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
55 Years
Study:
NCT05960266
Study Brief:
Protocol Section:
NCT05960266